Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 37

1.

Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas.

Glaas MF, Wiek C, Wolter LM, Roellecke K, Balz V, Okpanyi V, Wagenmann M, Hoffmann TK, Grässlin R, Plettenberg C, Schipper J, Hanenberg H, Scheckenbach K.

Anticancer Res. 2018 Mar;38(3):1317-1325.

PMID:
29491055
2.

Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype.

Asur RS, Kimble DC, Lach FP, Jung M, Donovan FX, Kamat A, Noonan RJ, Thomas JW, Park M, Chines P, Vlachos A, Auerbach AD, Smogorzewska A, Chandrasekharappa SC.

Mol Genet Genomic Med. 2018 Jan;6(1):77-91. doi: 10.1002/mgg3.350. Epub 2017 Nov 30.

3.

X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations.

McCauley J, Masand N, McGowan R, Rajagopalan S, Hunter A, Michaud JL, Gibson K, Robertson J, Vaz F, Abbs S, Holden ST.

Am J Med Genet A. 2011 Oct;155A(10):2370-80. doi: 10.1002/ajmg.a.33913. Epub 2011 Sep 9.

PMID:
21910217
4.

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker.

Cheung KL, Iles RK, Robertson JF.

World J Surg Oncol. 2010 May 13;8:38. doi: 10.1186/1477-7819-8-38.

5.

Fanconi anaemia complementation group B presenting as X linked VACTERL with hydrocephalus syndrome.

Holden ST, Cox JJ, Kesterton I, Thomas NS, Carr C, Woods CG.

J Med Genet. 2006 Sep;43(9):750-4. Epub 2006 May 5.

6.
7.

Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.

García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J.

Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27.

PMID:
18302019
8.

Human Mus81 and FANCB independently contribute to repair of DNA damage during replication.

Nomura Y, Adachi N, Koyama H.

Genes Cells. 2007 Oct;12(10):1111-22.

9.
10.

Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.

Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D.

Thromb Haemost. 2001 Mar;85(3):379-89.

PMID:
11307801
11.

The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex.

Huang M, Syed R, Stura EA, Stone MJ, Stefanko RS, Ruf W, Edgington TS, Wilson IA.

J Mol Biol. 1998 Feb 6;275(5):873-94.

PMID:
9480775
12.

The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution.

Muller YA, Ultsch MH, de Vos AM.

J Mol Biol. 1996 Feb 16;256(1):144-59.

PMID:
8609606
13.

Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers.

Smith IM, Mithani SK, Mydlarz WK, Chang SS, Califano JA.

ORL J Otorhinolaryngol Relat Spec. 2010;72(1):44-50. doi: 10.1159/000292104. Epub 2010 Mar 24.

14.

Evidence for at least eight Fanconi anemia genes.

Joenje H, Oostra AB, Wijker M, di Summa FM, van Berkel CG, Rooimans MA, Ebell W, van Weel M, Pronk JC, Buchwald M, Arwert F.

Am J Hum Genet. 1997 Oct;61(4):940-4.

15.

Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant.

Al-Balool HH, Weber D, Liu Y, Wade M, Guleria K, Nam PL, Clayton J, Rowe W, Coxhead J, Irving J, Elliott DJ, Hall AG, Santibanez-Koref M, Jackson MS.

Genome Res. 2011 Nov;21(11):1788-99. doi: 10.1101/gr.116442.110. Epub 2011 Sep 23.

16.

Evidence for subcomplexes in the Fanconi anemia pathway.

Medhurst AL, Laghmani el H, Steltenpool J, Ferrer M, Fontaine C, de Groot J, Rooimans MA, Scheper RJ, Meetei AR, Wang W, Joenje H, de Winter JP.

Blood. 2006 Sep 15;108(6):2072-80. Epub 2006 May 23.

17.

X-linked inheritance of Fanconi anemia complementation group B.

Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, Rooimans MA, Bier P, Hoatlin M, Pals G, de Winter JP, Wang W, Joenje H.

Nat Genet. 2004 Nov;36(11):1219-24. Epub 2004 Oct 24.

PMID:
15502827
18.

FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.

Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Takata M, Meetei AR, Wang W.

EMBO J. 2007 Apr 18;26(8):2104-14. Epub 2007 Mar 29.

19.

A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.

Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, Hoatlin M, Joenje H, de Winter JP, Wang W.

Nat Genet. 2005 Sep;37(9):958-63. Epub 2005 Aug 21.

20.

Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.

Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, Laghmani el H, Joenje H, McDonald N, de Winter JP, Wang W, West SC.

Mol Cell. 2007 Feb 9;25(3):331-43.

Supplemental Content

Support Center